Moffitt logo

Clinical Trials Search

Clinical Trial 19488

Cancer Type: Gastrointestinal Tumor
Interventions:

Study Type: Basic Science
Phase of Study: N/A
Investigators:

  • Heather Jim

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome

Summary

Objective

Aim 1: To conduct a genome-wide association study of nausea in cancer patients receiving moderately- or highly-emetogenic chemotherapy Aim 2: To identify biological pathways enriched by genetic variants associated with nausea Aim 3: To develop and validate a new algorithm to predict clinical risk of nausea based on host genetic, demographic, clinical, and patient-reported risk factors Aim 4: To explore associations of the pre-chemotherapy gut microbiome with nausea

Inclusion Criteria

  • > 18 years of age
  • Capable of speaking and reading English or Spanish
  • Diagnosed with a solid tumor
  • Chemotherapy naïve
  • Scheduled to receive moderately- or highly-emetogenic intravenous standard-dose chemotherapy as defined by the most recent version of NCCN antiemesis guidelines at City of Hope, Moffitt Cancer Center, The Ohio State University, UC Denver, or Rutgers University or their affiliates

  • Exclusion Criteria

  • Were treated with a systemic antibiotic in the past month
  • Have a diagnosis of inflammatory bowel disease
  • Have a nasogastric tube, or are receiving total parenteral nutrition